Drug-induced interstitial lung disease caused by olaparib: three case reports and review of the Japanese Adverse Drug Event Report database and literature
Abstract Background Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, has demonstrated effectiveness in treating ovarian, breast, and other cancers, particularly those with specific molecular subtypes including, but not limited to, BRCA1/2 mutations. Consequently, its utilization is expecte...
Main Authors: | Hiroshi Ishimoto, Noriho Sakamoto, Takashi Kido, Mutsumi Ozasa, Shin Tsutsui, Mayako Mori, Daichi Setoguchi, Shinnosuke Takemoto, Yasushi Obase, Yuji Ishimatsu, Chiharu Tomonaga, Kanako Matsumoto, Sachiko Morisaki, Kiyonori Miura, Hiroshi Mukae |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-08-01
|
Series: | BMC Pulmonary Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12890-023-02569-3 |
Similar Items
-
Pulmonary Langerhans cell histiocytosis diagnosed using transbronchial lung cryobiopsy: A case report
by: Keisuke Mine, et al.
Published: (2023-01-01) -
Profile of olaparib in the treatment of advanced ovarian cancer
by: Chase DM, et al.
Published: (2016-04-01) -
Bioanalytical method validation for therapeutic drug monitoring of olaparib in patients with ovarian cancer
by: Konrad Lewandowski, et al.
Published: (2024-06-01) -
Correlation between molar activity, injection mass and uptake of the PARP targeting radiotracer [18F]olaparib in mouse models of glioma
by: Chung Ying Chan, et al.
Published: (2022-10-01) -
Quantitative Characterization of Olaparib in Nanodelivery System and Target Cell Compartments by LC-MS/MS
by: Roberta Ottria, et al.
Published: (2019-03-01)